Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy

Yoshiro Fujiwara, Katsuyuki Kiura, Katsuyuki Hotta, Masahiro Tabata, Nagio Takigawa, Mitsune Tanimoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC). Patients and methods: We retrospectively reviewed the medical records of patients with NSCLC who received cytotoxic chemotherapy at Okayama University Hospital between January 2003 and March 2006. "Overweight" was defined as a body mass index (BMI) of 25 or more, according to the World Health Organization (WHO) criteria. We investigated the incidence and pattern of hepatic dysfunction during chemotherapy and evaluated the possible associations between hepatic dysfunction and several clinical factors, including BMI. Results: Of the 155 Japanese patients enrolled in this study, 19 (12%) were overweight. Grade 2 or worse hepatic dysfunction was observed in 5 of the 19 overweight patients (26%) but in only 13 of the 136 non-overweight patients (10%). A multivariate analysis demonstrated that a higher BMI significantly increased the risk of grade 2 or worse hepatic dysfunction after the initiation of cytotoxic chemotherapy (odds ratio = 4.04, 95% confidence intervals: 1.13-14.5, p = 0.032). Conclusion: Our data suggest that being overweight can influence the development of hepatic dysfunction in Japanese patients receiving cytotoxic chemotherapy for the treatment of NSCLC, although further investigation is required.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalLung Cancer
Volume55
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Liver
Body Mass Index
Medical Records
Multivariate Analysis
Odds Ratio
Confidence Intervals
Incidence

Keywords

  • Chemotherapy
  • Hepatic dysfunction
  • Lung cancer
  • Overweight
  • Risk factor

ASJC Scopus subject areas

  • Oncology

Cite this

Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy. / Fujiwara, Yoshiro; Kiura, Katsuyuki; Hotta, Katsuyuki; Tabata, Masahiro; Takigawa, Nagio; Tanimoto, Mitsune.

In: Lung Cancer, Vol. 55, No. 3, 03.2007, p. 343-348.

Research output: Contribution to journalArticle

@article{9331901845694df384230252fd1b0006,
title = "Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy",
abstract = "Purpose: The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC). Patients and methods: We retrospectively reviewed the medical records of patients with NSCLC who received cytotoxic chemotherapy at Okayama University Hospital between January 2003 and March 2006. {"}Overweight{"} was defined as a body mass index (BMI) of 25 or more, according to the World Health Organization (WHO) criteria. We investigated the incidence and pattern of hepatic dysfunction during chemotherapy and evaluated the possible associations between hepatic dysfunction and several clinical factors, including BMI. Results: Of the 155 Japanese patients enrolled in this study, 19 (12{\%}) were overweight. Grade 2 or worse hepatic dysfunction was observed in 5 of the 19 overweight patients (26{\%}) but in only 13 of the 136 non-overweight patients (10{\%}). A multivariate analysis demonstrated that a higher BMI significantly increased the risk of grade 2 or worse hepatic dysfunction after the initiation of cytotoxic chemotherapy (odds ratio = 4.04, 95{\%} confidence intervals: 1.13-14.5, p = 0.032). Conclusion: Our data suggest that being overweight can influence the development of hepatic dysfunction in Japanese patients receiving cytotoxic chemotherapy for the treatment of NSCLC, although further investigation is required.",
keywords = "Chemotherapy, Hepatic dysfunction, Lung cancer, Overweight, Risk factor",
author = "Yoshiro Fujiwara and Katsuyuki Kiura and Katsuyuki Hotta and Masahiro Tabata and Nagio Takigawa and Mitsune Tanimoto",
year = "2007",
month = "3",
doi = "10.1016/j.lungcan.2006.10.014",
language = "English",
volume = "55",
pages = "343--348",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Being overweight influences the development of hepatic dysfunction in Japanese patients with non-small-cell lung cancer undergoing cytotoxic chemotherapy

AU - Fujiwara, Yoshiro

AU - Kiura, Katsuyuki

AU - Hotta, Katsuyuki

AU - Tabata, Masahiro

AU - Takigawa, Nagio

AU - Tanimoto, Mitsune

PY - 2007/3

Y1 - 2007/3

N2 - Purpose: The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC). Patients and methods: We retrospectively reviewed the medical records of patients with NSCLC who received cytotoxic chemotherapy at Okayama University Hospital between January 2003 and March 2006. "Overweight" was defined as a body mass index (BMI) of 25 or more, according to the World Health Organization (WHO) criteria. We investigated the incidence and pattern of hepatic dysfunction during chemotherapy and evaluated the possible associations between hepatic dysfunction and several clinical factors, including BMI. Results: Of the 155 Japanese patients enrolled in this study, 19 (12%) were overweight. Grade 2 or worse hepatic dysfunction was observed in 5 of the 19 overweight patients (26%) but in only 13 of the 136 non-overweight patients (10%). A multivariate analysis demonstrated that a higher BMI significantly increased the risk of grade 2 or worse hepatic dysfunction after the initiation of cytotoxic chemotherapy (odds ratio = 4.04, 95% confidence intervals: 1.13-14.5, p = 0.032). Conclusion: Our data suggest that being overweight can influence the development of hepatic dysfunction in Japanese patients receiving cytotoxic chemotherapy for the treatment of NSCLC, although further investigation is required.

AB - Purpose: The aim of this study was to identify risk factors for hepatic dysfunction during cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer (NSCLC). Patients and methods: We retrospectively reviewed the medical records of patients with NSCLC who received cytotoxic chemotherapy at Okayama University Hospital between January 2003 and March 2006. "Overweight" was defined as a body mass index (BMI) of 25 or more, according to the World Health Organization (WHO) criteria. We investigated the incidence and pattern of hepatic dysfunction during chemotherapy and evaluated the possible associations between hepatic dysfunction and several clinical factors, including BMI. Results: Of the 155 Japanese patients enrolled in this study, 19 (12%) were overweight. Grade 2 or worse hepatic dysfunction was observed in 5 of the 19 overweight patients (26%) but in only 13 of the 136 non-overweight patients (10%). A multivariate analysis demonstrated that a higher BMI significantly increased the risk of grade 2 or worse hepatic dysfunction after the initiation of cytotoxic chemotherapy (odds ratio = 4.04, 95% confidence intervals: 1.13-14.5, p = 0.032). Conclusion: Our data suggest that being overweight can influence the development of hepatic dysfunction in Japanese patients receiving cytotoxic chemotherapy for the treatment of NSCLC, although further investigation is required.

KW - Chemotherapy

KW - Hepatic dysfunction

KW - Lung cancer

KW - Overweight

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=33847332205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847332205&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.10.014

DO - 10.1016/j.lungcan.2006.10.014

M3 - Article

VL - 55

SP - 343

EP - 348

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -